Sexual Health

PT-141Bremelanotide

The brain-driven libido peptide — counters GLP-1 induced sexual side effects via central mechanism, not blood flow.

What It Is

PT-141 (bremelanotide) is a melanocortin receptor agonist that acts centrally in the brain to boost sexual desire and arousal. It works fundamentally differently from PDE5 inhibitors like Viagra or Cialis (which target peripheral blood flow). The branded version, Vyleesi, is FDA-approved for premenopausal hypoactive sexual desire disorder (HSDD) in women.

Mechanism

Activates melanocortin receptors (primarily MC4R) in the central nervous system, which influence sexual desire pathways. Effect is on "wanting" sex rather than mechanical arousal or erection — meaningfully different from PDE5 inhibitor mechanism.

What Consumers Use It For

Restoring libido drop in women on GLP-1 medications (rapid weight loss can affect sexual desire)
Premenopausal HSDD (the FDA-approved Vyleesi indication)
Off-label use in men with desire-side issues that PDE5 inhibitors do not address

Legal & Regulatory Status (May 2026)

Vyleesi (branded bremelanotide) is FDA-approved for premenopausal HSDD in women. Compounded PT-141 is offered off-label via licensed telehealth with prescription. Off-label use in men is common but not FDA-approved.

Telehealth Providers & Pricing

Verified May 2026. Pricing varies by dose, plan length, and bundling. Always confirm directly with the provider before signup.

Boston Medical Group

Bremetide compounded via telehealth Rx

Hone Health

~$130/mo (men-focused)

SynergenX clinics

Compounded protocols, varies by location

TestDepot

$459 for 8-week supply

Vyleesi (branded)

$0-$99 for 4 doses with savings card; $290/dose cash

What the Evidence Actually Shows

Phase 3 trials supported Vyleesi FDA approval in women — increases in satisfying sexual events vs placebo. Smaller off-label studies in men show libido improvement. Notably, this is a desire drug, not a performance drug — it does not produce erections directly.

Typical Dosing Protocol

Subcutaneous injection 1-2 mg taken approximately 45 minutes before anticipated activity. Vyleesi caps at 8 doses per month. Nasal spray formats exist but are less effective due to absorption variability. Most consumer protocols are as-needed rather than daily.

Dosing should be confirmed by your prescribing physician — these are common consumer protocols, not medical advice.

What Real Users Report

Synthesized from Reddit (r/Peptides, r/Semaglutide, r/Tirzepatide) and forums, May 2025-2026:

Reddit users in 2025-2026 frequently report restored "mental wanting" — particularly women on GLP-1 medications who experienced libido drop with rapid weight loss. The most common complaint is nausea, which can be severe enough to ruin the timing for some users. A minority report skin darkening at injection sites or flushing.

Safety & Contraindications

Common side effects: nausea (notable), flushing, headache, temporary skin darkening or hyperpigmentation. Avoid in patients with uncontrolled hypertension or cardiovascular disease. Black box warning for blood pressure elevation. Not for use during pregnancy.

Best Reason to Add It

Directly counters GLP-1-induced libido drop via central brain pathways that PDE5 inhibitors do not affect. For users experiencing desire-side effects (especially women), this is one of the only options.

Biggest Red Flag

Nausea side effects can be severe enough to derail the timing for many users. Not a quick-fix like PDE5 inhibitors and requires precise pre-activity dosing. Skin darkening can be persistent.

Stacking note: Peptides are typically considered after a GLP-1 protocol is dialed in. If you have not started GLP-1 therapy yet, optimize that first. Compare GLP-1 telehealth pricing here before adding peptide protocols.

Other Peptides for GLP-1 Stackers

BPC-157 Ipamorelin + CJC-1295 TB-500 AOD-9604